Kymera to announce phase 2b atopic dermatitis trial results Monday
WATERTOWN, Massachusetts - Kymera Therapeutics is set to reveal the Phase 2b clinical trial outcomes for its oral STAT6 degrader, KT-621, on Monday, November 23, 2026, according to a press release. The study assessed the investigational drug's efficacy in patients suffering from moderate to severe atopic dermatitis. Kymera, a biopharmaceutical company based in Massachusetts, aims to issue a press release at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET.
The drug, known as a first-in-class, once-daily oral degrader of STAT6, targets IL-4/IL-13 signaling pathways. Kymera, established in 2016, is dedicated to creating oral small molecule degrader medicines for immunological conditions.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.